Moderna and Merck personalised melanoma vaccine cuts recurrence in trial
⏮ BeforePatients with melanoma face the risk of recurrence and spread after treatment.
✅ NowTrial data show the personalised vaccine delayed recurrence and distant metastasis.
In short
- Data released at the ESMO meeting show the Moderna-Merck personalised mRNA vaccine reduced recurrence-free survival.
- The vaccine also lengthened the time until distant metastasis occurred.
- The results arrived earlier than expected, according to the source's headline.
Why the Good News Desk likes this one
The vaccine is tailored to each patient's tumour, using mRNA technology. The trial data suggest it can delay both the return of melanoma and its spread to distant parts of the body. The source gives no approval status, so the benefit should be read as trial evidence.
Advertisement
From STAT
In data released at ESMO, the Moderna-Merck personalized mRNA cancer vaccine reduced recurrence-free survival and the time until distant metastasis occurred.
Ask this story
📜 The story so far
- 22 Oct 2026 Personalized Cancer Vaccine Cuts Melanoma Recurrence Risk by 42 Percent Where it started.
- 23 Oct 2026 Moderna mRNA vaccine almost halves risk of melanoma returning The same Moderna melanoma vaccine trial result is now described as almost halving recurrence risk, a rephrasing of the earlier 42 percent figure rather than a new development.
- 23 Oct 2026 Personalized mRNA vaccine cuts melanoma recurrence risk in late-stage trial The same personalized mRNA melanoma vaccine's 42% recurrence-risk reduction is now reported from a late-stage trial, with the risk figure restated as death too.
- 23 Oct 2026 Moderna and Merck personalised melanoma vaccine cuts recurrence in trial The same Moderna and Merck melanoma vaccine trial is reported again, now describing delayed return and spread of the cancer in the trial data.
- 23 Oct 2026 Personalised mRNA cancer vaccine cuts melanoma return risk by 42% The same 42% melanoma result is now reported with more detail, adding that it is a Phase III trial of the Keytruda-combined vaccine.
More like this
Advertisement